While current studies have focused on using GSTP1 as a potential marker for the early detection of prostate cancer, we propose that assessing DNA methylation of the GSTP1 promoter region, as well as expression of GSTP1, has the potential to be a useful tool for determining DNMTi efficacy in prostate cancer. The gene discussed is GSTP1; the disease is prostate cancer.